Metfendrazine (developmental code names HM-11, MO-482), also known as methphendrazine, is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine family.[1][2] It was investigated as an antidepressant, but was never marketed.
 | |
| Clinical data | |
|---|---|
| Other names | Methphendrazine; HM-11; MO-482; N-Aminomethamphetamine; Methamphetamine hydrazide; N-Amino-N-methylamphetamine |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C10H16N2 |
| Molar mass | 164.252 g·mol−1 |
Chemistry
editMetfendrazine, also known as methamphetamine hydrazide, is a phenethylamine, amphetamine, and hydrazine derivative.
It is an analogue and derivative of phenelzine (phenethylamine hydrazide) and pheniprazine (amphetamine hydrazide), as well as of phenethylamine, amphetamine, and methamphetamine.
References
edit- ^ Miquel J, Mijan CD (1962). "Metfendrazine, a new inhibitor of monoamine oxidase". Archivos del Instituto de Farmacología Experimental. 14. Madrid: 47–59.
- ^ Kothari NJ, Saunders JC, Kline NS, Griffen JA (October 1960). "A comparison of perphenazine, proketazine, nialamide and MO-482 in chronic schizophrenics". The American Journal of Psychiatry. 117 (4): 358–360. doi:10.1176/ajp.117.4.358. PMID 13753478.